OrigAMI-3: Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer
Condition: Colorectal Cancer
Sponsor: Janssen Research & Development, LLC
Full Title
Protocol 61186372COR3002: A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy
Study Treatment
EGFRxMET bispecific antibody Amivantamab vs Cetuximab or Bevacizumab
Given in combination with the FOLFIRI chemotherapy regimen
Eligibility/Info
KRAS, NRAS, and BRAF wild type unresectable or metastatic colorectal cancer previously treated with a fluoropyrimidine and oxaliplatin in the metastatic setting and with no history of treatment with an EGFR inhibitor or irinotecan.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
